


Isofraxidin

Cat. No.:	HY-N0774												
CAS No.:	486-21-5												
Molecular Formula:	C ₁₁ H ₁₀ O ₅												
Molecular Weight:	222.19												
Target:	COX; MMP; Toll-like Receptor (TLR); ERK												
Pathway:	Immunology/Inflammation; Metabolic Enzyme/Protease; MAPK/ERK Pathway; Stem Cell/Wnt												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (1125.16 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	4.5007 mL	22.5033 mL	45.0065 mL
		5 mM	0.9001 mL	4.5007 mL	9.0013 mL
	10 mM	0.4501 mL	2.2503 mL	4.5007 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (9.36 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (9.36 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Isofraxidin, a coumarin component from <i>Acanthopanax senticosus</i> , inhibits MMP-7 expression and cell invasion of human hepatoma cells. Isofraxidin inhibits the phosphorylation of ERK1/2 in hepatoma cells ^[1] . Isofraxidin attenuates the expression of iNOS and COX-2, Isofraxidin also inhibits TLR4/myeloid differentiation protein-2 (MD-2) complex formation ^[2] .		
IC₅₀ & Target	COX-2	TLR4	MMP-7
In Vitro	Isofraxidin inhibits expression of MMP-7 and in vitro cell invasion at a non-toxic level through inhibiting ERK1/2 phosphorylation in hepatoma cell lines ^[1] . Isofraxidin competitively inhibits TLR4/MD-2 complex formation, and thus TLR4/NF-κB signalling cascades. Isofraxidin has		

potential in the treatment of Osteoarthritis (OA)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Int Immunopharmacol. 2024 Mar 12:131:111814.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Yamazaki T, et al. Isofraxidin, a coumarin component from *Acanthopanax senticosus*, inhibits matrix metalloproteinase-7 expression and cell invasion of human hepatoma cells. *Biol Pharm Bull.* 2010;33(10):1716-22.

[2]. Jin J , et al. Isofraxidin targets the TLR4/MD-2 axis to prevent osteoarthritis development. *Food Funct.* 2018 Nov 14;9(11):5641-5652.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA